Sentinel node and positron emission tomography mapping in lung cancer

Semin Thorac Cardiovasc Surg. 2009 Winter;21(4):323-6. doi: 10.1053/j.semtcvs.2009.11.004.

Abstract

Radioguided lymph node mapping can potentially improve staging in locoregional non-small cell lung cancer. This is accomplished by using advanced pathologic techniques to detect micrometastases in selected thoracic lymph nodes. The use of isosulfan blue, technetium-99m and (18)F-fluorodeoxyglucose (FDG) as mapping agents have been reported. Despite several limitations in this technique, it may facilitate the selection of patients for novel therapies, resulting in improved outcomes for lung cancer patients.

Publication types

  • Review

MeSH terms

  • Carcinoma, Non-Small-Cell Lung / diagnostic imaging*
  • Carcinoma, Non-Small-Cell Lung / secondary*
  • Carcinoma, Non-Small-Cell Lung / therapy
  • Coloring Agents
  • Fluorodeoxyglucose F18
  • Humans
  • Lung Neoplasms / diagnostic imaging*
  • Lung Neoplasms / secondary*
  • Lung Neoplasms / therapy
  • Lymph Nodes / diagnostic imaging*
  • Lymphatic Metastasis
  • Neoplasm Staging
  • Positron-Emission Tomography*
  • Predictive Value of Tests
  • Prognosis
  • Radiopharmaceuticals
  • Rosaniline Dyes
  • Technetium

Substances

  • Coloring Agents
  • Radiopharmaceuticals
  • Rosaniline Dyes
  • Fluorodeoxyglucose F18
  • iso-sulfan blue
  • Technetium